The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Multiple Myeloma
MULTIPLE MYELOMA ADVISOR
FEATURED CONTENT
-
-
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments. -
The Unexpected Costs of Cancer Treatment: Out-of-Network Billing
The cancer field is not immune to the challenges of out-of-network and surprise billing. -
Transplant in Multiple Myeloma Deemed Safe in Older Patients — But Is It Necessary?
Multiple myeloma specialists are increasingly transplanting older adults based on performance status and other objective measures of health vs age alone. -
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
VIDEO SERIES
MULTIPLE MYELOMA NEWS
Single-Agent Daratumumab May Delay Progression of Smoldering Multiple Myeloma
Total Therapy Approach May Improve Transplant Outcomes in Patients With Myeloma
Reirradiation Rarely Required in Focal RT for Multiple Myeloma
Mass Spectrometry for Detection of Monoclonal Gammopathy of Undetermined Significance
Belantamab Mafodotin Gets Priority Review for Heavily Pretreated Multiple Myeloma
Want to read more?
Please login or register first to view this content.
Next post in Multiple Myeloma
